A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

Abstract Background Chronic kidney disease (CKD) patients with and without heart failure (HF) often present with hyperkalaemia (HK) leading to increased risk of hospitalisations, cardiovascular related events and cardiovascular-related mortality. Renin–angiotensin–aldosterone system inhibitor (RAASi...

Full description

Bibliographic Details
Main Authors: Thomas Ward, Ruth D. Lewis, Tray Brown, Garth Baxter, Antonio Ramirez de Arellano
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Nephrology
Subjects:
Hyperkalaemia
RAASi
Patiromer
Chronic kidney disease
Heart failure
Cost-effectiveness
Online Access:https://doi.org/10.1186/s12882-023-03088-3

Internet

https://doi.org/10.1186/s12882-023-03088-3

Similar Items